Evidence for copathogenicity as a mechanism for bacterial resistance

Infectious Diseases in Clinical Practice

Volumn 7, Issue SUPPL. 4, 1998, Pages

  Pichichero, Michael E ^a  

^a UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; BETA LACTAMASE; DICLOXACILLIN; PENICILLIN G;

ANTIBIOTIC RESISTANCE; ENZYME ACTIVITY; HUMAN; PHARYNGITIS; REVIEW; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS; TONSILLITIS; TREATMENT FAILURE;

EID: 0031767327     PISSN: 10569103     EISSN: None     Source Type: Journal    
DOI: 10.1097/00019048-199811004-00007     Document Type: Review

References (48)

1. Gastanaduy AS, Kaplan EL, Huwe BB, et al. Failure of penicillin to eradicate group A streptococci during an outbreak of pharyngitis. Lancet 1980;2:498-502.
2. Kaplan EL. Benzathine penicillin G for treatment of group A streptococcal pharyngitis: a reappraisal in 1985. Pediatr Infect Dis 1985;4:592-6.
3. Pichichero ME. The rising incidence of penicillin treatment failures in group A streptococcal tonsillopharyngitis: an emerging role for the cephalosporins? Pediatr Infect Dis J 1991;10(Suppl):50S-55S.
4. Bartlett JG, Mundy LM. Current concepts: community-acquired pneumonia. N Engl J Med 1995,333:1618-24.
5. Brook I, Frazier EH, Yeager JK. Microbiology of nonbullous impetigo. Pediatr Dermatol 1997;14:192-5.
6. Dagan R, Bar-David Y. Comparison of amoxicillin and clavulanic acid (Augmentin) for the treatment of nonbullous impetigo. Am J Dis Child 1989;143:916-8.
7. Demidovich CW, Wittler RR, Ruff ME, et al. Impetigo: current etiology and comparison of penicillin, erythromycin, and cephalexin therapies. Am J Dis Child 1990;144: 1313-5.
8. Pichichero ME Group A streptococcal tonsillopharyngitis: cost-effective diagnosis and treatment. Ann Emerg Med 1995;25.390-403.
9. Pichichero ME Explanations and therapies for penicillin failure in streptococcal pharyngitis. Clin Pediatr 1992; 31:642-9
10. Brook I. Emergence and persistence of β-lactamase-producing bacteria in the oropharynx following penicillin treatment. Arch Otolaryngol Head Neck Surg 1988;114. 667-70.
11. Eliasson I, Holst E, Molstad S, et al. Emergence and persistence of β-lactamase-producing bacteria in the upper respiratory tract in children treated with β-lactam antibiotics. Am J Med 1990;88(5A Suppl):51S-55S.
12. Reed BD, Huck W, Zazove P. Treatment of β-hemolytic streptococcal pharyngitis with cefaclor or penicillin: efficacy and interaction with β-lactamase-producing organisms in the pharynx. J Fam Pract 1991;32:138-44.
13. Block SL. Causative pathogens, antibiotic resistance and therapeutic considerations in acute otitis media Pediatr Infect Dis J 1997;16:449-56.
14. Brook I. The role of β-lactamase-producing bacteria in respiratory tract infections. Scand J Infect Dis Suppl 1988;57:41-9.
15. Brook I. Role of anaerobic β-lactamase-producing bacteria in upper respiratory tract infections. Pediatr Infect Dis J 1987;6:310-6.
16. Brook I. Microbiology of retropharyngeal abscesses in children. Am J Dis Child 1987;141:202-4.
17. Marchant CD. Spectrum of disease due to Branhamella catarrhalis in children with particular reference to acute otitis media. Am J Med 1990;88(5A Suppl):15S-19S.
18. Pichichero ME. Controversies in the treatment of streptococcal pharyngitis. Am Fam Physician 1990;42:1567-76.
19. Thornsberry C. The development of antimicrobial resistance in staphylococci. J Antimicrob Chemother 1988;21 (C Suppl):9-16.
20. Wallace RJ Jr, Nash DR, Steingrube VA. Antibiotic susceptibilities and drug resistance in Moraxella (Branhamella) catarrbalis. Am J Med 1990;88(5A Suppl): 46S-50S.
21. Simon HJ, Sakai W. Staphylococcal antagonism to penicillin-G therapy of hemolytic streptococcal pharyngeal infection: effect of oxacillin. Pediatrics 1963;31:463-9.
22. Kundsin RB, Miller JM. Significance of the Staphylococcus aureus carrier state in the treatment of disease due to group A streptococci. N Engl J Med 1964;271:1395-7.
23. Bryant RE, Rashad AL, Mazza JA, et al. β-Lactamase activity in human pus. J Infect Dis 1980;142:594-601.
24. Brook I. Presence of β-lactamase-producing bacteria and β-lactamase activity in abscesses. Am J Clin Pathol 1986; 86:97-101.
25. Hackman AS, Wilkins TD. In vivo protection of Fusobacterium necrophorum from penicillin by Bacteroides fragilis. Antimicrob Agents Chemother 1975;7:698-703.
26. Masuda G, Tomioka S. Possible β-lactamase activities detectable in infective clinical specimens. J Antibiot 1977; 30:1093-7.
27. O'Keefe JP, Tally FP, Barza M, et al. Inactivation of penicillin G during experimental infection with Bacteroides fragilis. J Infect Dis 1978;137:437-42.
28. Smith TD, Huskins WC, Kim KS, et al. Efficacy of β-lactamase-resistant penicillin and influence of penicillin tolerance in eradicating streptococci from the pharynx after failure of penicillin therapy for group A streptococcal pharyngitis. J Pediatr 1987;110:777-82.
29. Kaplan EL, Johnson DR. Eradication of group A streptococci from the upper respiratory tract by amoxicillin with clavulanate after oral penicillin V treatment failure. J Pediatr 1988;113:400-3.
30. Roos K, Grahn E, Holm SE. Evaluation of β-lactamase activity and microbial interference in treatment failures of acute streptococcal tonsillitis. Scand J Infect Dis 1986; 18:313-9.
31. Brook I, Yocum P. Bacteriology and β-lactamase activity in ear aspirates of acute otitis media that failed amoxicillin therapy [letter]. Pediatr Infect Dis J 1995;14.805-7.
32. Pichichero ME, Margolis PA A comparison of cephalosporins and penicillins in the treatment of group A β-hemolytic streptococcal pharyngitis: a meta-analysis supporting the concept of microbial copathogenicity. Pediatr Infect Dis J 1991;10:275-81.
33. Stillerman M. Comparison of oral cephalosporins with penicillin therapy for group A streptococcal pharyngitis. Pediatr Infect Dis 1986;5:649-54.
34. Matsen JM, Torstenson O, Siegel SE, et al. Use of available dosage forms of cephalexin in clinical comparison with phenoxymethyl penicillin and benzathine penicillin in the treatment of streptococcal pharyngitis in children. Antimicrob Agents Chemother 1974;6:501-6.
35. Pichichero ME, Disney FA, Aronovitz GH, et al. A multicenter, randomized, single-blind evaluation of cefuroxime axetil and phenoxymethyl penicillin in the treatment of streptococcal pharyngitis. Clin Pediatr 1987;26:453-8.
36. Pichichero ME. Cephalosporins are superior to penicillin for treatment of streptococcal tonsillopharyngitis: is the difference worth it? Pediatr Infect Dis J 1993;12:268-74.
37. Gooch WM III, McLinn SE, Aronovitz GH, et al. Efficacy of cefuroxime axetil suspension compared with that of penicillin V suspension in children with group A streptococcal pharyngitis. Antimicrob Agents Chemother 1993;37:159-63.
38. Block SL, Hedrick JA, Tyler RD. Comparative study of the effectiveness of cefixime and penicillin V for the treatment of streptococcal pharyngitis in children and adolescents. Pediatr Infect Dis J 1992;11:919-25
39. Pichichero ME, McLinn SE, Gooch WM III, and members of the Ceftibuten Pharyngitis International Study Group. Ceftibuten vs. penicillin V in group A β-hemolytic streptococcal pharyngitis. Pediatr Infect Dis J 1995; 14(Suppl):102S-107S
40. Dajani AS, Kessler SL, Mendelson R, et al. Cefpodoxime proxetil vs. penicillin V in pediatric streptococcal pharyngitis/tonsillitis. Pediatr Infect Dis J 1993,12.275-9.
41. Disney FA, Hanfling MJ, Hausinger SA. Loracarbef (LY163892) vs. penicillin VK in the treatment of streptococcal pharyngitis and tonsillitis. Pediatr Infect Dis J 1992;11(Suppl):20S-26S.
42. Milatovic D, Adam D, Hamilton H, et al. Cefprozil vs. penicillin V in treatment of streptococcal tonsillopharyngitis. Antimicrob Agents Chemother 1993;37:1620-3.
43. Pichichero ME, Cohen R. Shortened course of antibiotic therapy for acute otitis media, sinusitis and tonsillopharyngitis. Pediatr Infect Dis J 1997;16:680-95
44. Cockburn J, Reid AL, Bowman JA, et al. Effects of intervention on antibiotic compliance in patients in general practice. Med J Aust 1987,147:324-8.
45. Eisen SA, Miller DK, Woodward RS, et al The effect of prescribed daily dose frequency on patient medication compliance. Arch Intern Med 1990;150:1881-4.
46. Harrison CJ. Rational selection of antimicrobials for pediatric upper respiratory infections. Pediatr Infect Dis J 1995;14(Suppl):121S-129S.
47. Schwartz RH, Wientzen RL, Pedreira F, et al. Penicillin V for group A streptococcal pharyngotonsillitis: a randomized trial of seven vs. ten days' therapy. JAMA 1981;246: 1790-5.
48. Strömberg A, Schwan A, Cars O. Five vs. ten days treatment of group A streptococcal pharyngotonsiltitis. a randomized controlled clinical trial with phenoxymethylpenicillin and cefadroxil. Scand J Infect Dis 1988;20:37-46.